Skip to main content

Table 3 Baseline patient, tumor and treatment characteristics according to adjuvant chemotherapy administration

From: Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: axillary dissection versus no axillary dissection in patients with involved sentinel node

Test

 

All

ALND

SLNB

SLBN vs ALND

Category

N

n (%)

p value*

N

n (%)

N

n (%)

Odd Ratio95%CI

p value**

Age in class

<= 40

45

44(.98)

<.001

22

21(.95)

23

23(1.0)

> 999[< 0.01,> 999]

0.978

41–75

828

582(.70)

 

376

266(.71)

452

316(.70)

0.96[0.71, 1.30]

0.794

>  75

53

18(.34)

 

25

10(.40)

28

8(.29)

0.61[0.19,1.88]

0.387

Tumor size (mm)

<=10

143

64(.45)

 

57

27(.47)

86

37(.43)

0.84[0.43,1.64]

0.610

10–30

684

506(.74)

 

323

236(.73)

361

270(.75)

1.09[0.78,1.54]

0.608

> 30

96

73(.76)

<.001

41

34(.83)

55

39(.71)

0.51[0.19,1.37]

0.179

Histology type

Infiltrant ductal

748

543(.73)

 

340

246(.72)

408

297(.73)

1.02[0.74,1.41]

0.893

Infiltrant lobular

101

50(.50)

 

45

25(.56)

56

25(.45)

0.65[0.30,1.42]

0.279

Mixed

25

19(.76)

<.001

12

10(.83)

13

9(.69)

0.46[0.07,3.05]

0.425

Other

52

32(.62)

 

26

16(.62)

26

16(.62)

1.00[0.33,3.02]

1.000

SBR grade

Gr I

206

88(.43)

<.001

98

40(.41)

108

48(.44)

1.16[0.67,2.01]

0.600

Gr II

464

317(.68)

 

200

139(.70)

264

178(.67)

0.91[0.61,1.35]

0.635

Gr III

237

223(.94)

 

116

110(.95)

121

113(.93)

0.77[0.26,2.29]

0.640

LVI

No

275

235(.85)

<.001

130

110(.85)

145

125(.86)

1.14[0.58,2.22]

0.709

Yes

616

394(.64)

 

276

178(.64)

340

216(.64)

0.96[0.69,1.34]

0.805

Capsular Effraction

No

673

467(.69)

 

313

217(.69)

360

250(.69)

1.01[0.72,1.40]

0.974

Yes

167

122(.73)

0.355

75

56(.75)

92

66(.72)

0.86[0.43,1.72]

0.673

Hormonal receptors status

Negative

75

73(.97)

<.001

39

38(.97)

36

35(.97)

0.92[0.06,15.02]

0.955

Positive

837

568(.68)

 

377

257(.68)

460

311(.68)

0.97[0.73,1.30]

0.863

HER2 status

Negative

794

532(.67)

 

358

242(.68)

436

290(.67)

0.95[0.71,1.28]

0.747

Positive

102

98(.96)

<.001

52

50(.96)

50

48(.96)

0.96[0.13,7.02]

0.968

Tumor subtype (RH/HER2)

RH+/HER2+

75

72(.96)

 

36

35(.97)

39

37(.95)

0.53[0.05,6.05]

0.612

RH+/HER2-

743

486(.65)

 

332

218(.66)

411

268(.65)

0.98[0.72,1.33]

0.897

RH-/HER2+

26

26(1.0)

<.001

15

15(1.0)

11

11(1.0)

  

RH-/HER2-

45

44(.98)

 

22

22(1.0)

23

22(.96)

< 0.01[< 0.01,> 999.99]

0.978

Harvested SN, number

=1

365

253(.69)

 

165

115(.70)

200

138(.69)

0.97[0.62,1.51]

0.886

=2

303

205(.68)

 

142

96(.68)

161

109(.68)

1.00[0.62,1.63]

0.986

> 2

258

186(.72)

0.519

116

86(.74)

142

100(.70)

0.83[0.48,1.44]

0.509

Involved SN

<=2

891

619(.69)

 

406

285(.70)

485

334(.69)

0.94[0.71,1.25]

0.668

> 2

14

13(.93)

0.059

6

6(1.0)

8

7(.88)

< 0.01[< 0.01,> 999.99]

0.979

SN status

ITC

56

31(.55)

<.001

22

14(.64)

34

17(.50)

0.58[0.19,1.71]

0.322

Micro

289

164(.57)

 

133

76(.57)

156

88(.56)

0.97[0.61,1.55]

0.900

Macro

525

405(.77)

 

241

183(.76)

284

222(.78)

1.13[0.75,1.71]

0.544

Endocrine therapy

No

75

66(.88)

<.001

29

28(.97)

46

38(.83)

0.17[0.02,1.45]

0.106

Yes

653

420(.64)

 

302

192(.64)

351

228(.65)

1.06[0.77,1.46]

0.714

Trastuzumab

No

567

368(.65)

 

256

162(.63)

311

206(.66)

1.14[0.81,1.61]

0.463

Yes

83

83(1.0)

<.001

38

38(1.0)

45

45(1.0)

  

Breast Surgery

Mastectomy

160

120(.75)

0.099

73

55(.75)

87

65(.75)

0.97[0.47,1.98]

0.927

Conservative

766

524(.68)

 

350

242(.69)

416

282(.68)

0.94[0.69,1.28]

0.688

Radiotherapy

No

38

19(.50)

0.010

19

10(.53)

19

9(.47)

0.81[0.23,2.86]

0.749

Yes

867

604(.70)

 

390

273(.70)

477

331(.69)

0.97[0.73,1.30]

0.846

  1. *P value derived from Chi square test for categorical variables
  2. **P value derived from analysis including treatment group as received as single factor in logistic regression
  3. Abbreviations: ALND axillairy lymph node dissection, SLNB sentinel lymph node dissection alone, CI confidence interval
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us